Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. G. Richardson, M. Delforge, M. Beksac, P. Wen, J. L. Jongen, O. Sezer, E. Terpos, N. Munshi, A. Palumbo, S. V. Rajkumar, J. L. Harousseau, P. Moreau, H. Avet-Loiseau, J. H. Lee, M. Cavo, G. Merlini, P. Voorhees, W. J. Chng, A. Mazumder, S. UsmaniH. Einsele, R. Comenzo, R. Orlowski, D. Vesole, J. J. Lahuerta, R. Niesvizky, D. Siegel, M. V. Mateos, M. Dimopoulos, S. Lonial, S. Jagannath, J. Bladé, J. San Miguel, G. Morgan, K. C. Anderson, B. G M Durie, P. Sonneveld

Research output: Contribution to journalArticle

Abstract

Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions.

Original languageEnglish
Pages (from-to)595-608
Number of pages14
JournalLeukemia
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Peripheral Nervous System Diseases
Multiple Myeloma
Therapeutics
Incidence
Vinca Alkaloids
Radiculopathy
Thalidomide
Practice Management
Causality
Cisplatin
Appointments and Schedules
Pharmacology

Keywords

  • bortezomib
  • immunomodulatory drug
  • multiple myeloma
  • peripheral neuropathy
  • proteasome inhibitor
  • thalidomide

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., ... Sonneveld, P. (2012). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 26(4), 595-608. https://doi.org/10.1038/leu.2011.346

Management of treatment-emergent peripheral neuropathy in multiple myeloma. / Richardson, P. G.; Delforge, M.; Beksac, M.; Wen, P.; Jongen, J. L.; Sezer, O.; Terpos, E.; Munshi, N.; Palumbo, A.; Rajkumar, S. V.; Harousseau, J. L.; Moreau, P.; Avet-Loiseau, H.; Lee, J. H.; Cavo, M.; Merlini, G.; Voorhees, P.; Chng, W. J.; Mazumder, A.; Usmani, S.; Einsele, H.; Comenzo, R.; Orlowski, R.; Vesole, D.; Lahuerta, J. J.; Niesvizky, R.; Siegel, D.; Mateos, M. V.; Dimopoulos, M.; Lonial, S.; Jagannath, S.; Bladé, J.; Miguel, J. San; Morgan, G.; Anderson, K. C.; Durie, B. G M; Sonneveld, P.

In: Leukemia, Vol. 26, No. 4, 04.2012, p. 595-608.

Research output: Contribution to journalArticle

Richardson, PG, Delforge, M, Beksac, M, Wen, P, Jongen, JL, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, SV, Harousseau, JL, Moreau, P, Avet-Loiseau, H, Lee, JH, Cavo, M, Merlini, G, Voorhees, P, Chng, WJ, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, JJ, Niesvizky, R, Siegel, D, Mateos, MV, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, JS, Morgan, G, Anderson, KC, Durie, BGM & Sonneveld, P 2012, 'Management of treatment-emergent peripheral neuropathy in multiple myeloma', Leukemia, vol. 26, no. 4, pp. 595-608. https://doi.org/10.1038/leu.2011.346
Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr;26(4):595-608. https://doi.org/10.1038/leu.2011.346
Richardson, P. G. ; Delforge, M. ; Beksac, M. ; Wen, P. ; Jongen, J. L. ; Sezer, O. ; Terpos, E. ; Munshi, N. ; Palumbo, A. ; Rajkumar, S. V. ; Harousseau, J. L. ; Moreau, P. ; Avet-Loiseau, H. ; Lee, J. H. ; Cavo, M. ; Merlini, G. ; Voorhees, P. ; Chng, W. J. ; Mazumder, A. ; Usmani, S. ; Einsele, H. ; Comenzo, R. ; Orlowski, R. ; Vesole, D. ; Lahuerta, J. J. ; Niesvizky, R. ; Siegel, D. ; Mateos, M. V. ; Dimopoulos, M. ; Lonial, S. ; Jagannath, S. ; Bladé, J. ; Miguel, J. San ; Morgan, G. ; Anderson, K. C. ; Durie, B. G M ; Sonneveld, P. / Management of treatment-emergent peripheral neuropathy in multiple myeloma. In: Leukemia. 2012 ; Vol. 26, No. 4. pp. 595-608.
@article{b69b8cbf994d4e9a9a1400e60f2437ea,
title = "Management of treatment-emergent peripheral neuropathy in multiple myeloma",
abstract = "Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20{\%} of MM patients have PN at diagnosis and as many as 75{\%} may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions.",
keywords = "bortezomib, immunomodulatory drug, multiple myeloma, peripheral neuropathy, proteasome inhibitor, thalidomide",
author = "Richardson, {P. G.} and M. Delforge and M. Beksac and P. Wen and Jongen, {J. L.} and O. Sezer and E. Terpos and N. Munshi and A. Palumbo and Rajkumar, {S. V.} and Harousseau, {J. L.} and P. Moreau and H. Avet-Loiseau and Lee, {J. H.} and M. Cavo and G. Merlini and P. Voorhees and Chng, {W. J.} and A. Mazumder and S. Usmani and H. Einsele and R. Comenzo and R. Orlowski and D. Vesole and Lahuerta, {J. J.} and R. Niesvizky and D. Siegel and Mateos, {M. V.} and M. Dimopoulos and S. Lonial and S. Jagannath and J. Blad{\'e} and Miguel, {J. San} and G. Morgan and Anderson, {K. C.} and Durie, {B. G M} and P. Sonneveld",
year = "2012",
month = "4",
doi = "10.1038/leu.2011.346",
language = "English",
volume = "26",
pages = "595--608",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Management of treatment-emergent peripheral neuropathy in multiple myeloma

AU - Richardson, P. G.

AU - Delforge, M.

AU - Beksac, M.

AU - Wen, P.

AU - Jongen, J. L.

AU - Sezer, O.

AU - Terpos, E.

AU - Munshi, N.

AU - Palumbo, A.

AU - Rajkumar, S. V.

AU - Harousseau, J. L.

AU - Moreau, P.

AU - Avet-Loiseau, H.

AU - Lee, J. H.

AU - Cavo, M.

AU - Merlini, G.

AU - Voorhees, P.

AU - Chng, W. J.

AU - Mazumder, A.

AU - Usmani, S.

AU - Einsele, H.

AU - Comenzo, R.

AU - Orlowski, R.

AU - Vesole, D.

AU - Lahuerta, J. J.

AU - Niesvizky, R.

AU - Siegel, D.

AU - Mateos, M. V.

AU - Dimopoulos, M.

AU - Lonial, S.

AU - Jagannath, S.

AU - Bladé, J.

AU - Miguel, J. San

AU - Morgan, G.

AU - Anderson, K. C.

AU - Durie, B. G M

AU - Sonneveld, P.

PY - 2012/4

Y1 - 2012/4

N2 - Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions.

AB - Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions.

KW - bortezomib

KW - immunomodulatory drug

KW - multiple myeloma

KW - peripheral neuropathy

KW - proteasome inhibitor

KW - thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84859632261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859632261&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.346

DO - 10.1038/leu.2011.346

M3 - Article

C2 - 22193964

AN - SCOPUS:84859632261

VL - 26

SP - 595

EP - 608

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -